Arbutus Biopharma plans to repurchase up to US$230 million of its common stock through a modified Dutch auction tender offer, offering shareholders between US$5 and US$5.75 per share in cash. The company expects the offer to begin around Aug. 24 and expire around Sept. 29, unless extended or terminated, with funding from cash on hand. CEO Lindsay Androski linked the shareholder return to Arbutus's March 2026 settlement with Moderna, from which Arbutus received approximately US$178 million in July, including litigation-cost reimbursement. Arbutus and exclusive licensee Genevant Sciences continue patent litigation against Pfizer and BioNTech over lipid nanoparticle technology used in COVID-19 vaccines. The company's shares were up 6.92% at US$5.09 at publication, according to Benzinga Pro data.